Yuyu Pharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
November 14, 2023 at 02:40 am EST
Share
Yuyu Pharma, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was KRW 0.00032 million compared to negative sales of KRW 0.00044 million a year ago. Net loss was KRW 2,731.21 million compared to KRW 2,085.78 million a year ago. Basic loss per share from continuing operations was KRW 172 compared to KRW 130 a year ago. Diluted loss per share from continuing operations was KRW 172 compared to KRW 130 a year ago. Basic loss per share was KRW 172 compared to KRW 130 a year ago.
For the nine months, negative sales was KRW 0.00005 million compared to sales of KRW 0.00041 million a year ago. Net loss was KRW 6,094.34 million compared to KRW 3,778.51 million a year ago. Basic loss per share from continuing operations was KRW 387 compared to KRW 240 a year ago. Diluted loss per share from continuing operations was KRW 387 compared to KRW 240 a year ago. Basic loss per share was KRW 387 compared to KRW 240 a year ago.
Yuyu Pharma, Inc. is a Korea-based company engaged in the provision of pharmaceutical products. The Company produces prescription drugs such as circulatory improvement agents, antiplatelet agents, osteoporosis drugs, antiulcerants, bone metabolism ameliorants, gout preparative drugs, antidepressants, anti-diabetic agents, antitubercular agents, antihypertensive agents, angina pectoris drugs, antibiotics, hemorrhoidal and varicose preparations, topical corticosteroids and others, as well as non-prescription drugs such as vitamins and digestive agents. It also provides healthcare supplements and quasi drugs. In addition, the Company is involved in the provision of medicines for geriatric diseases such as osteoporosis, dementia, stroke and others.
YUYU PHARMA, INC. 
